Arecor presents at EASD 2020


21-09-2020

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart,NovoRapid®,and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual meeting which will be held from 21-25 September 2020.

Abstract #55 is available online.

Dr Eva Svehlikova, Medical Director of the Clinical Trials Unitat the Medical University of Graz and Investigator for the ARE-247-101 study, said: “AT247 has clearly demonstrated faster insulin absorption with an accelerated Pharmacokinetic (PK) and Pharmacodynamic (PD) profile compared to NovoRapid®and Fiasp®.  AT247 has the potential to significantly improve postprandial glucose control and flexibility of insulin dosing. Potential  clinical  benefits for avoiding  hypo  and hyperglycaemia need to be confirmed in further clinical studies.This early evidence suggests that AT247 may facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes.”

Oral Presentation of Abstract #55:
Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart and fast Insulin aspart

Presenting Author: Dr Eva Svehlikova
Session: OP10 Developing Better Insulins
Date and Time: Tuesday, 22 September, 2020, beginning at 14:30 CET


Sarah Howell, Chief Executive Officer of Arecor, added: “Presenting the successful results of our Phase 1 study of AT247 at EASD demonstrates the clear potential for our ultra-rapid acting insulin.  We believe that AT247’s superior profile will improve both treatment and healthcare outcomes for people living with Type 1 diabetes.  As  treatment  delivery  systems  continue  to  evolve,  we  believe  that AT247’s favourable profile over current treatments may play a pivotal role in advancing the delivery of care, with the potential to enable the artificial pancreas, which could significantly reduce th eburden of self-management for people living with diabetes.”

About AT247

AT247 is an investigational novel meal-time insulin formulation, that aims to significantly accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels.It has been designed to achieve PK/PD properties that more closely match the physiological insulin mealtime response of a person without diabetes.

The  double-blind,  randomised,  single  dose,  three-period  cross  over  Phase  I  clinical  study  (EudraCT:2018-003934-34) compared  the  PK/PD  profiles  of  AT247  to  NovoRapid®  and Fiasp®  in  19  men  with Type  I  diabetes.    The  trial  was conducted  in  a  glucose  clamp  setting  at  The  Medical  University  of  Graz  and  Joanneum  Research  in  Austria,  an internationally recognised centre of excellence in the field of diabetes research.  

The PK/PD profile for  AT247  was  accelerated compared  with both NovoRapid® and  Fiasp®.    AT247  was  more  rapidly absorbed from the injection site than both NovoRapid® and Fiasp®. Following dosing with AT247, insulin was detected in the blood 12 minutes (p=0.0004) earlier than following injection with NovoRapid®and 2 minutes (p=0.0003) earlier than  following  injection  with Fiasp®.    This  earlier  appearance  in  the  blood  was  matched  by  a  similarly  significantly accelerated onset of glucose lowering action for AT247; 23 minutes (p=0.0004) earlier than NovoRapid® and 9 minutes (p=0.0006)  earlier  than  Fiasp®.    Importantly,  the  early  (within  60  minutes)  glucose  lowering  action after  dosing  with AT247  was  fourfold  (p=0.0004)  greater  than  with  NovoRapid® and  two  fold  (p=0.0009)  greater  than  with  Fiasp®.   No safety signals were detected.
The next step on the accelerated development pathway for AT247 will be to explore its potential as the ideal insulin for use in pump and fully closed loop delivery (artificial pancreas) systems. Current best-in-class insulins are simply not fast enough acting to adequately control blood glucose within the artificial pancreas system around meal-times.  Therefore, there is a critical unmet need for even faster acting insulins, such as AT247, to enable a true artificial pancreas system which do not require a manual intervention by the patient around meal-times.

About EASD

EASD holds its Annual Meeting in a different European city each year with more than 15,000 delegates from over 130 countries attending. The scientific programme includes more than 1,200 talks and presentations on the latest results in diabetes research by leading experts in the field.

 

Advancing today's therapies to enable healthier lives.

Arecor Therapeutics Plc